Literature DB >> 8826852

Cyclin E overexpression, a negative prognostic factor in breast cancer with strong correlation to oestrogen receptor status.

N H Nielsen1, C Arnerlöv, S O Emdin, G Landberg.   

Abstract

Cyclin E is a G1 cyclin which has been proposed to be one of the key regulators of the important G1/S transition, and could consequently be a potential deregulated molecule in tumours. Recently, it has been observed that cyclin E is overexpressed in a variety of malignancies including breast cancer and that several isoforms of the protein exists. In this study we have characterised the cyclin E expression in 114 tumour specimens from patients with primary breast cancer using Western blotting. Various expression of cyclin E was observed among tumours and a group of 27 patients out of 100 patients with stage I-III disease, identified as having tumours with high cyclin E levels, had a significantly increased risk of death and relapse from breast cancer (P = 0.0002 and P = 0.015 respectively). Even in the subgroup of axillary node-negative patients the cyclin E level was of prognostic importance. There was also a strong association between cyclin E expression and oestrogen receptor status (P < 0.00001), and tumours with high cyclin E expression were in general oestrogen receptor negative, suggesting a potential role for cyclin E in mechanisms responsible for oestrogen-independent tumour growth.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8826852      PMCID: PMC2074748          DOI: 10.1038/bjc.1996.451

Source DB:  PubMed          Journal:  Br J Cancer        ISSN: 0007-0920            Impact factor:   7.640


  42 in total

1.  Growth factor, steroid, and steroid antagonist regulation of cyclin gene expression associated with changes in T-47D human breast cancer cell cycle progression.

Authors:  E A Musgrove; J A Hamilton; C S Lee; K J Sweeney; C K Watts; R L Sutherland
Journal:  Mol Cell Biol       Date:  1993-06       Impact factor: 4.272

2.  Amplification of cyclin genes in colorectal carcinomas.

Authors:  F S Leach; S J Elledge; C J Sherr; J K Willson; S Markowitz; K W Kinzler; B Vogelstein
Journal:  Cancer Res       Date:  1993-05-01       Impact factor: 12.701

3.  Mammary hyperplasia and carcinoma in MMTV-cyclin D1 transgenic mice.

Authors:  T C Wang; R D Cardiff; L Zukerberg; E Lees; A Arnold; E V Schmidt
Journal:  Nature       Date:  1994-06-23       Impact factor: 49.962

Review 4.  Cyclin gene expression and growth control in normal and neoplastic human breast epithelium.

Authors:  R L Sutherland; C K Watts; E A Musgrove
Journal:  J Steroid Biochem Mol Biol       Date:  1993-12       Impact factor: 4.292

Review 5.  How do breast cancers become hormone resistant?

Authors:  K B Horwitz
Journal:  J Steroid Biochem Mol Biol       Date:  1994-06       Impact factor: 4.292

6.  p21 is a universal inhibitor of cyclin kinases.

Authors:  Y Xiong; G J Hannon; H Zhang; D Casso; R Kobayashi; D Beach
Journal:  Nature       Date:  1993-12-16       Impact factor: 49.962

7.  Levels of retinoblastoma protein expression in newly diagnosed acute myelogenous leukemia.

Authors:  S M Kornblau; H J Xu; W Zhang; S X Hu; M Beran; T L Smith; J Hester; E Estey; W F Benedict; A B Deisseroth
Journal:  Blood       Date:  1994-07-01       Impact factor: 22.113

8.  Chromosome t(11;14)(q13;q32) breakpoints in centrocytic lymphoma are highly localized at the bcl-1 major translocation cluster.

Authors:  M E Williams; S H Swerdlow; T C Meeker
Journal:  Leukemia       Date:  1993-09       Impact factor: 11.528

9.  Acceleration of the G1/S phase transition by expression of cyclins D1 and E with an inducible system.

Authors:  D Resnitzky; M Gossen; H Bujard; S I Reed
Journal:  Mol Cell Biol       Date:  1994-03       Impact factor: 4.272

10.  Cyclin E, a potential prognostic marker for breast cancer.

Authors:  K Keyomarsi; N O'Leary; G Molnar; E Lees; H J Fingert; A B Pardee
Journal:  Cancer Res       Date:  1994-01-15       Impact factor: 12.701

View more
  32 in total

1.  Novel splice variants of cyclin E with altered substrate specificity.

Authors:  D C Porter; K Keyomarsi
Journal:  Nucleic Acids Res       Date:  2000-12-01       Impact factor: 16.971

2.  CENP-F expression is associated with poor prognosis and chromosomal instability in patients with primary breast cancer.

Authors:  Sallyann L O'Brien; Ailís Fagan; Edward J P Fox; Robert C Millikan; Aedín C Culhane; Donal J Brennan; Amanda H McCann; Shauna Hegarty; Siobhan Moyna; Michael J Duffy; Desmond G Higgins; Karin Jirström; Göran Landberg; William M Gallagher
Journal:  Int J Cancer       Date:  2007-04-01       Impact factor: 7.396

Review 3.  Prognosis and prediction of response in breast cancer: the current role of the main biological markers.

Authors:  A Ravaioli; L Bagli; A Zucchini; F Monti
Journal:  Cell Prolif       Date:  1998 Jun-Aug       Impact factor: 6.831

4.  Multifaceted regulation of cell cycle progression by estrogen: regulation of Cdk inhibitors and Cdc25A independent of cyclin D1-Cdk4 function.

Authors:  J S Foster; D C Henley; A Bukovsky; P Seth; J Wimalasena
Journal:  Mol Cell Biol       Date:  2001-02       Impact factor: 4.272

5.  Immunohistochemical expression of cyclin E in endometrial adenocarcinoma (endometrioid type) and its clinicopathological significance.

Authors:  N Kato; J Watanabe; T Jobo; Y Nishimura; T Fujisawa; Y Kamata; H Kuramoto
Journal:  J Cancer Res Clin Oncol       Date:  2003-04-08       Impact factor: 4.553

6.  Expression of cyclins E1 and E2 during mouse development and in neoplasia.

Authors:  Y Geng; Q Yu; W Whoriskey; F Dick; K Y Tsai; H L Ford; D K Biswas; A B Pardee; B Amati; T Jacks; A Richardson; N Dyson; P Sicinski
Journal:  Proc Natl Acad Sci U S A       Date:  2001-10-30       Impact factor: 11.205

7.  PKCalpha expression is a marker for breast cancer aggressiveness.

Authors:  Gry Kalstad Lønne; Louise Cornmark; Iris Omanovic Zahirovic; Göran Landberg; Karin Jirström; Christer Larsson
Journal:  Mol Cancer       Date:  2010-04-14       Impact factor: 27.401

8.  Classical and Novel Prognostic Markers for Breast Cancer and their Clinical Significance.

Authors:  Pankaj Taneja; Dejan Maglic; Fumitake Kai; Sinan Zhu; Robert D Kendig; Elizabeth A Fry; Kazushi Inoue
Journal:  Clin Med Insights Oncol       Date:  2010-04-20

9.  Overexpression of POLQ confers a poor prognosis in early breast cancer patients.

Authors:  Geoff S Higgins; Adrian L Harris; Remko Prevo; Thomas Helleday; W Gillies McKenna; Francesca M Buffa
Journal:  Oncotarget       Date:  2010-07

10.  Increased expression of cyclin E is associated with an increased resistance to doxorubicin in rat fibroblasts.

Authors:  A Sgambato; A Camerini; G Pani; R Cangiano; B Faraglia; G Bianchino; B De Bari; T Galeotti; A Cittadini
Journal:  Br J Cancer       Date:  2003-06-16       Impact factor: 7.640

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.